Abstract. We studied binding and degradation of labeled platelet thrombospondin (TSP) by normal and variant bovine aorta endothelial (BAE) cells.
1. Abbreviations used in this paper: BAE, bovine aorta endothelial; TSP, thrombospondin. cular endothelial cells of adult dermis contained less TSP than matrices of neonatal foreskin microvascular endothelial cells (27) . The regulation of TSP synthesis by cells in culture is modulated by factors affecting the cell cycle, as evidenced by observations that synthesis of TSP was greater in cultures of subconfluent cells than in cultures of density-arrested cells (47) and was transiently enhanced when platelet-derived growth factor was given to serum-starved cultures (2, 36) . TSP amplified the mitogenic effect of epidermal growth factor towards vascular smooth muscle cells (37) . Thus, TSP appears to have important effects on cells, especially under conditions in which there is active tissue modeling or healing. The mechanisms by which TSP has its effects on cells are unknown.
A previous paper from our laboratory described binding of TSP to fibroblast monolayers and to isolated matrices derived from fibroblast cultures (40) . Binding to the intact cell layers was transient, and bound TSP was rapidly degraded to a q'CA-soluble form (40) . Binding of radiolabeled TSP to the cell layers was not saturable because of extensive binding of TSP to extraceilular matrix at higher TSP concentrations. However, degradation of radiolabeled TSP was saturable and exhibited characteristics of well-studied examples of receptor-mediated endocytosis (40) . In subsequent experiments, we found that bovine aorta endothelial (BAE) cells could be used to study cellular binding and degradation of TSP without the complication of binding of TSP to extracellular matrix. The matrix formed by BAE cells is located primarily on the basal surfaces of the cells and therefore is not as accessible to exogenous molecules as the matrix of cultured fibroblasts. The BAE culture system is of physiologic and pathophysiologic relevance because vascular endothelium would be exposed to high concentrations of TSP during hemostatic and thrombotic events and perhaps also during neovascularization. We hypothesized, on the basis of previous studies (40) , that heparin-like molecules functioned as thrombospondin receptors. The heparan sulfate proteoglycans of BAE cells have been well characterized (38, among others). Therefore, we studied binding and degradation of TSP by BAE cells in considerable detail. Both events seem to be mediated by a celt surface molecule which has the characteristics of a heparan sulfate proteoglycan.
Materials and Methods

Materials
The following were purchased: DME and Ham's FI2 medium (Gibco Laboratories, Grand Island, NY); FBS (Hyctone Laboratories, Sterile Systems, Inc, Logan, UT); vitronectin (Calbiochem-Behring Corp., San Diego, CA); trypsin, BSA, fucoidan, heparin (porcine intestinal mucosa), chondroitin sulfate, hyaluronic acid, and dextran sulfate (tool wt 500,000) (Sigma Chemical Co., St. Louis, MO); hyaluronidase, chondroitinase ABC, and heparitinase (Miles Laboratories, Elkhart, IN); FITC (Cappet Laboratories, Cochranville, PA); rabbit antibodies to human factor VIIIrelated antigen (Dako Corp., Santa Barbara, CA, or Calbiochem-Behring Corp.); and rhodamine-or FITC-labeled secondary antibodies (Jackson Laboratories, Avondale, PA). Monoclonat antibodies to muscle-specific and smooth muscle-specific actins (22) were provided by Dr. Allen Gown (University of Washington, Seattle, WA). Carrier-free sodium 525I was obtained from New England Nuclear (Boston, MA).
Purification of TSP and Other Proteins
TSP was purified from the reteasate of thrombin-stimulated human platelets by affinity chromatography on heparin-agarose and gel filtration in the presence of0A mM calcium chloride, according to a previously published procedure (49) . The purification also resulted in good yields of platelet factor 4 (obtained by eluting the heparin-agarose with 2 M sodium chloride) and beta-thromboglobulin precursor (separated from TSP on the P-300 gel filtration column) (49) . The amino terminal sequence of the beta-thromboglobulin, kindly determined by Dr. Karna Skortensgaard, was predominantly (>95%) Asn-Leu-Ala-Lys-Gly-Lys-Glu-Glu; i.e., it contained four residues at the amino terminus which are largely missing from beta-throm.. bogtobulin obtained from outdated platelets (11) . Fibronectin was purified from a plasma protein side fraction by heat precipitation and chromatogra--phy on DEAE-cellulose (44) . Fibrinogen was purified from plasma by precipitation with ammonium sulfate, followed by DEAE-cellulose chromatography (43) .
Preparation of Iodinated and Fluoresceinated TSP
TSP was iodinated with ~ZSl by the chloramine T method (40) and repurifled by affinity chromatography on heparin-agarose in the presence of 0.1 mM calcium chloride. The labeled protein was >96% precipitabte by 10% "IV_A and appeared intact on SDS-polyacrylamide gels (28) analyzed by autoradiography.
[t~I]TSP ranged from 0.2 to 1 gCi/l~g protein sp act.
TSP was dialyzed against 0.05 M carbonate, pH 9.5, 0.15 M sodium chloride, and conjugated to FITC at a concentration of 30 ~tg fluorochrome/mg protein for 1 h at 24~ with continuous gentle rocking. Free FITC was separated from FrI'C-TSP by dialysis against 0.01 M Tris chloride, pH 7.4, 0.15 M sodium chloride, 0.1 mM calcium chloride. Examination of FITC-TSP on SDS-polyacrylamide gels under ultraviolet illumination revealed a single fluorescent band migrating at the same position as purified TSP.
Preparation of Whole Blood Serum and Plasma-derived Serum
Sera were prepared from blood obtained from a volunteer donor and placed in a glass tube containing no additive or a polypropylene tube containing acid citrate-dextrose (60) . Whole blood serum was prepared by centrifugation of the retracted clot in the glass tube after incubation for 3 h at room temperature. Plasma in acid citrate-dextrose was collected by centrifugation at 2,400 g for 1 h at 4~ Remaining platelets were removed by centrifugation for 3 min in a microfuge. The plasma was clotted for 60 rain at 370C by addition of calcium chloride to a final concentration of 20 mM. Serum was separated from the clot by centrifugation. Neither whole blood nor plasma-derived serum was cytotoxic in assays in which BAlE cells were incuhated for 2 d in media containing the sera at 10% concentration. TSP concentrations in the sera, determined by quantitative ELISA (26) , were as follows: whole blood serum, 23.3 ~tg/ml; and plasma-derived serum, 0.82 ~tg/ml.
Cells
Normal and variant BAE cells (gifts of Dr. Robert Auerbach, University of Wisconsin) were isolated from aortas obtained at local abbatoirs using collagenase according to an established protocol (9) and initially characterized by the method of Voyta et al. (61) . Cells were cultured in DME containing 4,500 rag/liter glucose, 2 mM glntamine, and 20% FBS and were used between passages 6 and 12. Human foreskin fibroblasts (provided by Dr. B. Lynn Allen-Hoffman, University of Wisconsin) were cultured in Ham's FI2 medium supplemented with 15 % FBS.
Both normal and variant BAE cultures stained for factor VIII-related antigen and sorted as one peak when stained with t,t-dioetedecyl-3,3,3',Ytetramethyl indocarbocyanine perclorate-labeled acetylated low density lipoprorein (DiI-Ac-LDL) and analyzed by fluorescence-activated cell sorting (kindly performed by Dr. Robert Auerbach's laboratory) (61) . Cells were negative when stained with antibodies speeifie for muscle and smooth muscle celt actins (22) . These results indicated that both of our cultures were endothelial cells without detectable contamination with smooth muscle cells. Normal BAE cells have a typical cobblestone morphology at confluence (Fig. 1 a) , whereas the variant BAE cells had an atypical morphology consisting of cords of noncontact-inhibited cells which piled up above and around the cobblestone monolayers upon reaching confluence (Fig. 1 b) . The relative number of variant cells in preconfluent and newly confluent cultures remained constant with the passage number. The variant BAE cells appear to differ from the "sprouters" described by Sehgartz (58) in that the elongated cells in the cords were present in preconfluent and newly confluent cultures, whereas sprout cells appear in cultures maintained afar confluence. When the normal BAE strain was kept past confluence, cells exhibiting typical sprouting morphology were observed.
When doing binding or degradation assays (see below), cells in replicate plates were enumerated in a microscopic counting chamber after trypsinization.
Fluorescence Microscopy
Cells were grown to confluence on glass coverslips and fixed with 100% methanol for 5 rain at -20~ Cells were stained for the presence of factor VIII-related antigen using rabbit polyelonal antibodies to human factor VIII-related antigen at either a 1:50 (Dako Corp.) or 1:100 (CalbiochemBehring Corp.) dilution in the presence of 0.1% ovalbumin. Cells were washed three times with 0.01 M Tris-buffered saline, pH 7.2, and stained with FITC-labeled goat anti-rabbit IgG antibody. Murine monoclonal antibodies to muscle-specific and smooth muscle-specific actins were used at the dilutions suggested by Dr. Gown and detected with a secondary FITClabeled antibody against mouse IgG. Coverslips were mounted onto glass slides using 50% glycerol and examined by epifluorescence using a Nikon Optiphot microscope equipped with a UFX-II camera.
Cells were incubated with DiI-Ac-LDL at 10 l~g/ml for I-4 h at T/*C in a 5 % CO2 atmosphere, rinsed, and fixed according to the protocol of Voyta et al. (61) . Coverslips were mounted and examined by fluorescence microscopy using excitation and barrier filters appropriate for rhodamine fluorescence. Cells on coverslips were also incubated with FITC-labeled TSP at 10 ~tg/ml at 37~ in 5% CO2 under various conditions. Coverslips were washed with DME with 0.2% BSA before fixation with 4% paraformaldehyde in 0.t M phosphate buffer, pH 7.4.
Binding Assays
Binding assays were performed on confluent monolayers in 35-ram tissue culture dishes as follows. Monolayers were rinsed twice with DME containing 0.2% BSA, 1 ml of a binding mixture containing [ml]TSP and unlabeled TSP in DME containing 0.2% BSA was added, and cells were incubated at either 37 incubation, cell layers were washed 4 times with ice-cold DME containing 0.2% BSA and solubilized overnight with 1 ml 1 N sodium hydroxide. Solubilized material was removed, and plates were washed with an additional 1 ml of 1 N sodium hydroxide. The radioactivity in the pooled extracts was then determined using a gamma counter.
Binding assays were performed on cells in suspension in some experiments. Monolayer cells at confluence were harvested with either 2.2 mM EDTA or EDTA and various concentrations of trypsin as described below, pelleted by centrifugation, and resuspended in DME containing 0.2 % BSA. After resnspension, cells were greater than 97% viable as determined by dye exclusion with Trypan blue. Cells (0.5-1 x 106/100 Ixi) were added to microfuge tubes containing a 1-ml mixture of DME, 0.2% BSA, ~25I-labeled TSP, and the appropriate amount of unlabeled TSP. The microfuge tubes ware precoated with 2 % BSA to minimize nonspecific binding. The suspensions were incubated at 37~ in 5% CO2 with frequent inversion. At the end of the incubation period, cells were pelleted by centfifugation for 2 min in a microfuge (Eppendorf, Brinkmann Instruments, Inc., Westbury, NY). Medium was removed, and the cell pellets were put on ice and washed three times with ice-cold DME containing 0.2 % BSA with minimal disturbance of the pellets. Radioactivity remaining in the cell pellet was measured.
Nonspecific binding was routinely determined in the presence of I lag/ml heparin rather than with an excess of unlabeled TSP (see Results). In no instance did binding of radioactivity to the tissue culture plates in the absence of heparin and cells exceed the nonspecific binding in the presence of heparin and cells. All samples were run in duplicate, Each experiment was performed a minimum of two times.
Enzymatic Pretreatment of Cells
Cells to be treated with enzymes before suspension binding assays were released from confluent rnonolayers with 2.2 mM EDTA and resuspended in DME containing 0,2% BSA. Aliquots of cells in l-ml vol were then treated at 37~ for either 5 min with increasing concentrations of trypsin or for 3 h with heparitinase, chondroitinase ABC, or hyaluronidase diluted in DME containing 0.2% BSA, The reaction was stopped by pelleting the cells in a microfuge, removing the enzyme in the supernatant, and washing the pellet once with DME containing 0.2% BSA. When trypsin was used, a fivefold excess (wt/wt) of soybean trypsin inhibitor was added before centrifugation. Cells were gently resuspended in DME containing 0.2% BSA and used in the binding assays described above. Aliquots of cells were checked for viability by the Trypan blue exclusion method, Control ceils were treated by the same protocols, except that the enzymes were omitted.
Assay of Degradation
Degradation of [~2~I]TSP was determined from the amount of radioactivity in the medium which became soluble in 10% TCA after incubation with cells (40)~ Duplicates of each experimental point were done. Degradation was monitored during a time period when the degradation was linear.
Results
Localization of FITC-TSP Bound to BAE Cells
BAE cells were incubated with 10 lag of FITC-labeled TSP at 37~ for different periods of time, washed, fixed, and examined by fluorescence microscopy to determine the localization of TSP bound to cells in monolayer. Staining was primarily in a punctate pattern with no detectable binding to fibrillar matrix (Fig. 1 c) . Addition of 10 lag/ml heparin simultaneously with FITC-TSP blocked binding. Little FITC-TSP was seen when cells were incubated for 1 h with FITC-TSP, washed, and incubated an additional 3 h in the absence of FITC-TSP (Fig. 1 d) .
Time Course of Binding of TSP to Cells
Binding of [eSI]TSP to normal BAE ceils at 3"/~ rapidly increased over the first 15 min and remained fairly constant for up to 4 h (Fig. 2 A) . Binding to variant BAE cells reached a maximum between 45 and 60 rain and decreased thereafter (Fig. 2 B) . Degradation of [uSI]TSP by normal BAE cells, as monitored by the appearance of TCA-soluble radioactivity in the medium, was first detected at 60 min. The amount of TCA-soluble radioactivity increased linearly over the next 3 h (not shown). Degradation of labeled TSP by variant BAE cells was apparent by 45 min of incubation at 37~ and increased linearly for the next 3 h (not shown). Binding to both cell types at 4~ was maximal at 120 min; no degradation was evident at this temperature (not shown).
Inhibition of TSP Binding by Various Macromolecules
Increasing amounts of unlabeled TSP competitively inhibited binding of [t25I]TSP to cells in monolayer (Table I) suspension (not shown). In competition assays, 100 lxg/ml of unlabeled TSP inhibited binding of labeled TSP, 0.1 IJg/ml, to monolayers by 65 %. Several other molecules, including heparin, fucoidan, platelet factor 4, and beta-thromboglobulin, also inhibited binding of labeled TSP to cells (Table I) . Heparin at a concentration as low as 0.10 I~g/ml competed for 50% of the binding of 0.1 I~/ml [=SI]TSP to 1 • 106 cells in monolayer (Fig. 3) . Treatment of monolayers with heparin resulted in prompt (<15 rain) release into the medium of 80% of the labeled TSP that had bound over the preceding 60 rnin (not shown). Fucoidan, which was shown previously to be an inhibitor of TSP binding to sulfatides of erythrocyte membranes (51), was more effective than heparin in blocking the binding of [t25I]TSP to cells (Fig. 3) . Chondroitin sulfate, at a considerably higher concentration than heparin or fucoidin, inhibited binding, whereas dextran sulfate and hyaluronic acid did not (Table I) . Platelet factor 4, which was shown previously to bind specifically to endothelial cells (10), inhibited total binding of TSP by ~70% (Fig.  4 A) . Platelet factor 4 and heparin had no inhibitory effect when present at an 1:1 (wt/wt) ratio (Fig. 4 A) . Beta-thromboglobulin was as effective as platelet factor 4 in inhibiting of TSP binding to variant endothelial cells (Table I) . Beta- thromboglobulin and heparin did not neutralize one another as inhibitors in the TSP-binding assay (not shown). Whole blood serum was more effective than serum derived from platelet-poor plasma (plasma serum) in blocking TSP binding to cells (Table I) . As determined by ELISA, plasma serum had a TSP concentration 25-fold lower than whole blood serum. The differences in platelet factor 4 and betathromboglobulin concentrations between plasma serum and whole blood serum, determined by commercial radioimmunoassay kits, were even greater (data not shown). Fibrinogen and fibronectin, plasma proteins that are known to interact with TSP, did not compete for binding of TSP to cells (Table  I) . Vitronectin also did not compete with TSP for binding to cells (Table I) .
Saturation of Binding of TSP to Cells in Monolayer
[t2SI]TSP bound to both normal (Fig. 5 ) and variant (data not shown) BAE cells in a saturable manner. Binding to fibroblast monolayers, done in parallel assays, was not saturable. The two BAE cell strains had similar dissociation constants (KdS) as determined by Scatchard analysis, but the variant strain cells had sixfold more binding sites (Table II) . These estimations of binding kinetics assume that one molecule of TSP binds to one binding site, assume that heparin will compete for all specific binding, and ignore the contribution of internalized TSP. Inasmuch as >80% of cellassociated TSP was promptly released upon addition of heparin, the contribution of internalized TSP to the calculation of the number of binding sites/cell was small.
Degradation of TSP
The degradation of [12SI]TSP by cells at 37~ was estimated by the increase in TCA-soluble radioactivity in the medium at 240 rain as compared with 60 rain. The velocity of degrada- tion was linear over this interval. Degradation of TSP by the two endothelial cell strains, and also by fibroblasts, was saturable and amenable to analysis by Lineweaver-Burke plots (Fig. 6 ). The V~x of normal BAE cells in monolayer was t3-fold less than the V,~ of variant BAE ceils although the constants of degradation (Kms) were similar (Table UI) , When normal BAE cells were incubated with TSP for 60 min, washed, and incubated without TSP, 50% of bound TSP was degraded in •2 h (not shown) and 80% of bound TSP was degraded in 5 h. Degradation was partially inhibited by monensin or chloroquine at 10 "~ M (not shown). When degradation was inhibited by the lysomotropic agents, label accumulated in the cell layer. As described above, degradation was not detectable in cultures incubated at 4~
As shown in Table III , the/(ms obtained by LineweaverBurke analysis closely corresponded to the/Gs of binding for the two endothelial cell strains. Agents which inhibited binding of TSP to cells also inhibited degradation of TSP with parallel dose-response curves. This was true for heparin or fucoidan (Fig. 3) , platelet factor 4 in the presence or absence of heparin (Fig. 4) , and serum derived from whole blood or platelet-poor plasma (not shown).
Biruling of TSP by Cells in Suspension
Cells released from the substratum with trypsin, 500 [tg/ml, and 2.2 mM EDTA were allowed to repair from the trypsin treatment for 30--40 min and then assayed for binding of [z2q]TSP. TSP binding to BAE cells and fibroblasts suspended in this manner was saturable. The BAE cells had Kas that were 5-10-fold higher in affinity as compared to cells in monolayer (Table IV) . There were less binding sites on the suspended cells than on the monolayer cells. Variant BAE cells at 4~ bound TSP with the same kinetics as variant BAE cells at 37~
Sensitivity of TSP, binding Sites to Enzymatic Digestion
Variant BAE cells which were suspended with 2.2 mM EI~A and no trypsin had binding constants similar to variant BAE cells in monolayer (Table IV) . Normal BAE cells could be released from the substratum with EDTA alone but did not exhibit saturable binding in suspension binding after release.
When EDTA-suspended cells were treated for 5 min with trypsin, washed, and then incubated with 2.2 nM [~25I]TSP (1 ~ml), the trypsin treatment was found to cause decreases in the binding of TSP at trypsin concentrations as low as 50 I.tg/ml ffig. 7). Treatment of cells with increasing doses of heparitinase for 3 h at 37~ also resulted in a decrease in the binding of TSP to the cells (Fig. 7) , When cells were first expose(, to trypsin and then to increasing doses of heparitinase, there was not an additive reduction in binding (Fig. 7) . There was no proteolytic degradation of labeled TSP by heparitinase when the ligand was treated with enzyme in solution and then analyzed by PAGE followed by autoradiography (not shown). Treatment of cells with chondroitinase ABC (Fig. 7) or hyaluronidase (not shown) did not reduce the amounts of TSP bound to cells in suspension. Cells in monolayer also showed dose-dependent reduction of TSP binding when pretreated with heparitinase. This was most evident when the cells were incubated with 10 lxg/ml cycloheximide both during the enzyme treatment and during the subsequent binding assay. Such treatment resulted in 53 % reduction of binding.
Discussion
[~2SlITSP bound to monolayers of endothelial cells in a specific and saturable manner indicative of a receptormediated process. The binding was primarily to the endothelial cells themselves, as assessed by fluorescence microscopy of bound FITC-TSP, with very little, if any, binding to matrix. Most of the [L~q]TSP bound to BAE monolayers after a short incubation was released promptly when the cell layers were washed and incubated further with heparin. If heparin was absent during the second incubation, most of the bound TSP was degraded to "l'CA-soluble products, Thus, the results with endothelial cells were different from the results with fibroblast cultures, in which 40-50% of TSP binding was to a slowly turning-over extracellutar matrix pool (40) . The difference between fibroblasts and endothelial cells in monolayer is most likely due to differences in the types and location of extracellular matrix. BAE cultures have less extensive matrix formation than fibroblast cultures, and the bulk of the endothelial cell matrix is not accessible to exogenous proteins because it is located on the basal side of the cells. We were able to demonstrate saturability of [~2Sl]TSP binding to suspended human foreskin fibroblasts or normal BAE cells stripped of extracellular matrix by trypsinization (Table IV) , whereas binding to monolayer fibroblasts or to normal BAE cells suspended with EDTA in the absence of trypsin was not saturable. As discussed below, however, TSP may bind to molecules on trypsinized cells in suspension which are different from the molecules which mediate binding and degradation of TSP by cells in monolayer. Degradation of TSP by eudothelial cells was saturable and inhibited by chloroquine or incubation of cells in the cold, as has been previously described for degradation of TSP by fibroblasts (40) . The following observations indicate that the cellular moiety which mediates binding of TSP by endothelial cells in monolayer at 37~ also mediates degradation of TSP: Kds of binding were the same as the K,~s; the variant BAE cells both bound more TSP and degraded more TSP as compared to the normal cells; and binding and degradation of TSP were suppressed in parallel by a number of experimental conditions. Binding constants were estimated under less than ideal conditions. We were limited in the amount of TSP we could purify, and some of our preparations of TSP aggregated at concentrations >100 lag/ml when >0.5 mM calcium ion was present. Therefore, we could not routinely use an excess of unlabeled TSP to estimate nonspecific binding and instead defined specific binding as that inhibited by hepafin. The cultures would be expected to accumulate a small amount of endogenous TSP during the assays (42) because protein synthesis w~s not blocked; the possible contribution of this TSP was ignored. Nevertheless, we were able to obtain reproducible and self-consistent results (Table II) . In particular, the Ks of binding (45 nM, Table II) agreed well with the concentrations of unlabeled TSP that caused 50% inhibition of binding of labeled TSP (55-110 nM, Table I) .
Heparin, fucoidan, platelet factor 4, and beta-thromboglobulin all caused less binding and degradation of TSP by cells. Chondroitin sulfate also inhibited binding and degradation of TSP, although higher concentrations were required. Dextran sulfate and hyaluronic acid did not inhibit. These results differ from experiments reported by Roberts et al. (56) , in which heparin, fucoidan, and dextran sulfate, but not chondroitin sulfate, inhibited binding of TSP to sulfatides. Three adhesive proteins known to bind to TSP and/or to cells, (i.e., fibrinogen, fibronectin, and vitronectin) did not inhibit binding of TSP. Thus, the interaction of TSP with cells is probably independent of the interactions of cells with the adhesive proteins. The inhibitor), effect of whole blood serum on binding and degradation of TSP is likely a sum of the inhibitory effects of platelet factor 4 and beta-thromboglobulin, inasmuch as the combined concentration of these 2 proteins in whole serum is ~20 Ixg/ml (46) .
The major TSP-binding site on endothelial cells was sensitive to digestion by trypsin or heparitinase. Chondroitinase ABC and hyaluronidase had no effect. A decrease in binding of platelet factor 4 to endothelial cells after heparitinase treatment has also been reported (10). No additive decrease in TSP binding was observed in cells which were treated with both trypsin and heparitinase. This result suggests that the trypsin-sensitive binding site is the same as the heparitinasesensitive binding site. The higher affinity, lower capacity sites that were unmasked when suspended cells were treated with trypsin and/or heparitinase may involve molecules, such as sulfatides, distinct from those that mediate binding to cells in monolayer.
The inhibitory effects of heparin, heparin-binding proteins, and heparitinase all point to a heparinqike molecule on the endothelial cell surface as a receptor for TSP. Recently, we had the opportunity to study the binding and degradation of TSP by Chinese hamster ovary (CHO) cell mutants defective in glycosaminoglycan biosynthesis and found that mutants lacking heparan sulfate were unable to bind or degrade TSP (50 and Murphy-Ultrich, J. E., L. G. Westrick, J. D. Esko, and D. E Mosher, manuscript submitted for publication). Thus, we think that the TSP receptor on Figure 7 . Effects of enzymatic treatment on the ability of endothelial cells to bind TSE Variant endothelial cells were released from monolayer with 2.2 mM EDTA and resuspended in DME containing 0.2% BSA. Aliquots of the suspension were treated at 37~ for 5 min with increasing concentrations of trypsin (~x) or for 3 h with increasing concentrations of chondmitinase ABC (Ha) or heparitinase (e) according to the protocol described in Materials and Methods. In addition, cells were released from monolayer with 50 t~g/ml trypsin and 0.5 mM ED'fA before treatment with increasing concentrations of heparitinase (o). Enzyme-treated ceils and controls were incubated in suspension with labeled 1 Ixg/ml TSP for 60 min at 37~ and the bound fraction was separated as de- 
